Bangkok Genomics Innovation PCL (BKK:BKGI) Gross Margin % : 45.36% (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Bangkok Genomics Innovation PCL Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Bangkok Genomics Innovation PCL's Gross Profit for the three months ended in Mar. 2024 was ฿30.99 Mil. Bangkok Genomics Innovation PCL's Revenue for the three months ended in Mar. 2024 was ฿68.32 Mil. Therefore, Bangkok Genomics Innovation PCL's Gross Margin % for the quarter that ended in Mar. 2024 was 45.36%.

The historical rank and industry rank for Bangkok Genomics Innovation PCL's Gross Margin % or its related term are showing as below:

BKK:BKGI' s Gross Margin % Range Over the Past 10 Years
Min: 29.81 Med: 45.82 Max: 51.68
Current: 45.36

During the past 5 years, the highest Gross Margin % of Bangkok Genomics Innovation PCL was 51.68%. The lowest was 29.81%. And the median was 45.82%.

BKK:BKGI's Gross Margin % is ranked worse than
51.67% of 209 companies
in the Medical Diagnostics & Research industry
Industry Median: 46.64 vs BKK:BKGI: 45.36

Bangkok Genomics Innovation PCL had a gross margin of 45.36% for the quarter that ended in Mar. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Bangkok Genomics Innovation PCL was 0.00% per year.

Bangkok Genomics Innovation PCL Gross Margin % Historical Data

The historical data trend for Bangkok Genomics Innovation PCL's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bangkok Genomics Innovation PCL Gross Margin % Chart

Bangkok Genomics Innovation PCL Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Margin %

29.81

44.32

51.68

47.31

Bangkok Genomics Innovation PCL Quarterly Data
	Dec20	Dec21	Mar22	Dec22	Mar23	Dec23	Mar24
Gross Margin %	Get a 7-Day Free Trial			55.17	-	55.16	-	45.36

Competitive Comparison of Bangkok Genomics Innovation PCL's Gross Margin %

For the Diagnostics & Research subindustry, Bangkok Genomics Innovation PCL's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bangkok Genomics Innovation PCL's Gross Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Bangkok Genomics Innovation PCL's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Bangkok Genomics Innovation PCL's Gross Margin % falls into.

Bangkok Genomics Innovation PCL Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Bangkok Genomics Innovation PCL's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	116.1	/	245.39
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(245.39 - 129.286)	/	245.39
	=	47.31 %

Bangkok Genomics Innovation PCL's Gross Margin for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )	=	Gross Profit (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	31	/	68.321
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(68.321 - 37.328)	/	68.321
	=	45.36 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Bangkok Genomics Innovation PCL (BKK:BKGI) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Bangkok Genomics Innovation PCL had a gross margin of 45.36% for the quarter that ended in Mar. 2024 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Bangkok Genomics Innovation PCL Gross Margin % Related Terms

Thank you for viewing the detailed overview of Bangkok Genomics Innovation PCL's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bangkok Genomics Innovation PCL (BKK:BKGI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Bangkok Genomics Innovation PCL (BKK:BKGI) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3689 Rama 4 Road, Phra Khanong Subdistrict, Khlong Toei Subdistrict, Bangkok, THA, 10110

Website

https://www.bangkokgenomics.com

Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products).